Ouster enters its August 6 earnings window with an unusual split: a freshly upgraded Street view colliding with short sellers who have spent the past month quietly adding to their positions.
The analyst story moved sharply today. Oppenheimer raised its price target on Ouster from $42 to $57 — a 36% lift — while maintaining its Outperform rating, bringing the firm's target well above the stock's current $41.97 close. That move pushes the consensus mean target to $49, implying roughly 17% upside from current levels. Rosenblatt had already lifted its own target to $53 in late May. The direction of travel from the bulls is clear: the Rev8 lidar cycle and the ARGUS Interception partnership are being repriced higher. Cantor Fitzgerald moved the other way after Q1 results in May, cutting to Neutral from Overweight — a reminder that not everyone is convinced the near-term financials support the long-term story. The bear case is straightforward: Ouster guided for a roughly 25% sequential revenue drop this quarter following the Stereolabs acquisition, with gross margins under pressure and Non-GAAP EPS still negative.
Short interest tells a less comfortable story than the bullish analyst revisions might suggest. Bears have added steadily: short interest has climbed 12% over the past week and nearly 15% over the past month, reaching 11% of the free float as of July 14. That is a meaningfully elevated level for a stock trading near $42. The pace of rebuilding — from roughly 5.2 million shares short in mid-June to 6.6 million now — tracks closely with the stock's recovery from its May post-earnings drop. Despite the increased short interest, the borrow market remains loose. Availability runs at roughly 271% of outstanding short interest, well above the stress threshold, and cost to borrow is just 0.45% — barely above the risk-free rate. Shorts are not fighting for stock to borrow; there is plenty of room in the lending pool. The ORTEX short score has drifted up to 55 from around 52 a week ago, consistent with a build in pessimistic positioning but far from extreme.
Options positioning adds a mild cautionary note without being alarming. The put/call ratio has edged up to 0.47, running about 1.3 standard deviations above its 20-day average of 0.43. That is modestly more defensive than the recent norm but nowhere near the 52-week high of 1.11. Call activity still dominates, keeping the overall options tone tilted toward upside participation rather than hedging — a configuration that fits the Oppenheimer target lift better than it fits the short-building narrative.
The insider picture adds texture worth noting. On June 12, nearly the entire senior team — CEO Charles Pacala, CFO Ken Gianella, CTO Mark Frichtl, COO Darien Spencer, and General Counsel Megan Chung — all sold shares on the same day at $38.82. Gianella's sale alone was $2.1 million. The CFO holds 853,690 shares as of the most recent filing. Cluster selling by this many C-suite names on a single date at a price roughly 8% below today's close is worth flagging, even if routine 10b5-1 plans may explain some of the activity. BlackRock added 255,000 shares in Q2, bringing its stake to 7.9% of the company, while Mirae Asset took an almost entirely new position of roughly 500,000 shares — both signals of institutional interest on the buy side.
Earnings history shows the stock is capable of large moves in either direction. The June 17 report produced a 9% next-day gain; the May 7 print delivered a 14% single-day drop before recovering strongly over the following week. With the next report due August 6, the setup heading in will be worth watching closely — particularly how short interest evolves and whether the Oppenheimer target lift attracts further institutional buying to offset the sellers who have been quietly rebuilding their positions.
See the live data behind this article on ORTEX.
Open OUST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
